[Lu-177]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

- Hofman, Michael S., Emmett, Louise, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Weickhardt, Andrew, Scott, Andrew M., Lee, Sze-Ting, Kwan, Edmond M., Azad, Arun A., Ramdave, Shakher, Redfern, Andrew D., Sandhu, Shahneen, Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Y., McJannett, Margaret M., Stockler, Martin R., Violet, John A., Williams, Scott G., Iravani, Amir, Martin, Andrew J., Davis, Ian D., Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Ng, Siobhan

18F-FDG PET-CT performed before and during radiation therapy of head and neck squamous cell carcinoma: are they independent or complementary to each other?

- Min, Myo, Lin, Peter, Lee, Mark, Shon, Ivan Ho, Lin, Michael, Forstner, Dion, Tieu, Minh Thi, Chicco, Andrew, Bray, Victoria, Fowler, Allan

Prognostic role of metabolic parameters of ¹⁸F-FDG PET-CT scan performed during radiation therapy in locally advanced head and neck squamous cell carcinoma

- Min, Myo, Lin, Peter, Lee, Mark T., Shon, Ivan Ho, Lin, Michael, Forstner, Dion, Bray, Victoria, Chicco, Andrew, Tieu, Minh Thi, Fowler, Allan